File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: Erlotinib as salvage treatment after failure to first-line gefitinib in non-small cell lung cancer

TitleErlotinib as salvage treatment after failure to first-line gefitinib in non-small cell lung cancer
Authors
Issue Date2009
PublisherLippincott Williams & Wilkins.
Citation
The 13th World Conference on Lung Cancer (WCLC), San Francisco, CA., 31 July-4 August 2009. In Journal of Thoracic Oncology, 2009, v. 4 n. 9, suppl. 1, p. S719, abstract no. P1.263 How to Cite?
AbstractBACKGROUND: Chemotherapy is the mainstay treatment for advanced non-small cell lung cancer (NSCLC). Gefitinib, an epidermal growth factor receptor - tyrosine kinase inhibitor (EGFR-TKI), has been recently shown to be effective as a first-line treatment in Asian patients with advanced NSCLC, especially for those with favourable clinical features such as female, non-smoker and adenocarcinoma. However, resistance to gefitinib ensues invariably and there is little evidence as for the effectiveness of subsequent salvage treatment. PURPOSE: To evaluate the efficacy of erlotinib, another EGFR-TKI, after failed first-line use of gefitinib. METHOD: Retrospective review of NSCLC patients with favourable clinical features who received gefitinib as first-line treatment and subsequent salvage treatment with erlotinib. RESULTS: A total of 21 patients with NSCLC were included in the study. Among them, 18 (85.7%) patients had disease control with gefitinib and 11 (52.4%) patients with erlotinib. There was an association between the disease control with gefitinib and erlotinib (p=0.016). The disease control rate of erlotinib was independent of the chemotherapy use between the two EGFR-TKIs. CONCLUSION: For NSCLC patients with favourable clinical features, erlotinib was effective in those who had prior disease control with first-line gefitinib.
Persistent Identifierhttp://hdl.handle.net/10722/133873
ISSN
2015 Impact Factor: 5.04
2015 SCImago Journal Rankings: 2.597

 

DC FieldValueLanguage
dc.contributor.authorWong, MKY-
dc.contributor.authorLo, AI-
dc.contributor.authorLam, WK-
dc.contributor.authorLam, B-
dc.contributor.authorIp, MSM-
dc.contributor.authorHo, JCM-
dc.date.accessioned2011-06-02T02:10:06Z-
dc.date.available2011-06-02T02:10:06Z-
dc.date.issued2009-
dc.identifier.citationThe 13th World Conference on Lung Cancer (WCLC), San Francisco, CA., 31 July-4 August 2009. In Journal of Thoracic Oncology, 2009, v. 4 n. 9, suppl. 1, p. S719, abstract no. P1.263-
dc.identifier.issn1556-0864-
dc.identifier.urihttp://hdl.handle.net/10722/133873-
dc.description.abstractBACKGROUND: Chemotherapy is the mainstay treatment for advanced non-small cell lung cancer (NSCLC). Gefitinib, an epidermal growth factor receptor - tyrosine kinase inhibitor (EGFR-TKI), has been recently shown to be effective as a first-line treatment in Asian patients with advanced NSCLC, especially for those with favourable clinical features such as female, non-smoker and adenocarcinoma. However, resistance to gefitinib ensues invariably and there is little evidence as for the effectiveness of subsequent salvage treatment. PURPOSE: To evaluate the efficacy of erlotinib, another EGFR-TKI, after failed first-line use of gefitinib. METHOD: Retrospective review of NSCLC patients with favourable clinical features who received gefitinib as first-line treatment and subsequent salvage treatment with erlotinib. RESULTS: A total of 21 patients with NSCLC were included in the study. Among them, 18 (85.7%) patients had disease control with gefitinib and 11 (52.4%) patients with erlotinib. There was an association between the disease control with gefitinib and erlotinib (p=0.016). The disease control rate of erlotinib was independent of the chemotherapy use between the two EGFR-TKIs. CONCLUSION: For NSCLC patients with favourable clinical features, erlotinib was effective in those who had prior disease control with first-line gefitinib.-
dc.languageeng-
dc.publisherLippincott Williams & Wilkins.-
dc.relation.ispartofJournal of Thoracic Oncology-
dc.rightsThis is a non-final version of an article published in final form in (provide complete journal citation)-
dc.titleErlotinib as salvage treatment after failure to first-line gefitinib in non-small cell lung canceren_US
dc.typeConference_Paperen_US
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=1556-0864&volume=4&issue=9, suppl. 1&spage=S719, abstract no. P1.263&epage=&date=2009&atitle=Erlotinib+as+salvage+treatment+after+failure+to+first-line+gefitinib+in+non-small+cell+lung+cancer-
dc.identifier.emailWong, MKY: drmwong@HKUCC-COM.hku.hk-
dc.identifier.emailLam, WK: lamwk@hku.hk-
dc.identifier.emailLam, B: lambing@HKUCC.hku.hk-
dc.identifier.emailIp, MSM: msmip@hku.hk-
dc.identifier.emailHo, JCM: jhocm@hku.hk-
dc.identifier.doi10.1097/JTO.0b013e3181b9c77e-
dc.identifier.hkuros172607-
dc.identifier.volume4-
dc.identifier.issue9, suppl. 1-
dc.identifier.spageS719-
dc.identifier.epageS719-
dc.description.otherThe 13th World Conference on Lung Cancer (WCLC), San Francisco, CA., 31 July-4 August 2009. In Journal of Thoracic Oncology, 2009, v. 4 n. 9, suppl. 1, p. S719, abstract no. P1.263-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats